PREDICTIONS OF RESPONSIVENESS TO EGFR INHIBITORS

摘要

Coordinated over-expression of the EGFR pathway predicts susceptibility to EGFR inhibitors in cancer. This suggests that a phenomenon of pathway- rather than oncogene-addiction predicts vulnerability to EGFR inhibition in cancer. This demonstrates the powerful value of unbiased systems biology approaches in drug development and have important implications for the management of use of these agents in cancers.